Media headlines about Recro Pharma (NASDAQ:REPH) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Recro Pharma earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.1602201932657 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Recro Pharma Inc (REPH) to Post FY2017 Earnings of ($2.43) Per Share, Oppenheimer Forecasts (americanbankingnews.com)
- Recro Pharma (REPH) Earns Outperform Rating from Analysts at CIBC (americanbankingnews.com)
- Recro Pharma (REPH) Earns Outperform Rating from Analysts at UBS Group (americanbankingnews.com)
- Recro Pharma Inc (REPH) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Recro Pharma (REPH) Now Covered by Analysts at Oppenheimer (americanbankingnews.com)
Shares of Recro Pharma (NASDAQ:REPH) traded down $0.40 during mid-day trading on Friday, reaching $8.30. The company had a trading volume of 166,435 shares, compared to its average volume of 108,309. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.59. The stock has a market capitalization of $151.46, a price-to-earnings ratio of -3.86 and a beta of -0.60. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35.
A number of research firms have recently weighed in on REPH. Zacks Investment Research lowered Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Oppenheimer began coverage on Recro Pharma in a research note on Tuesday. They set an “outperform” rating and a $19.00 price objective for the company. CIBC began coverage on Recro Pharma in a research note on Wednesday. They set an “outperform” rating and a $19.00 price objective for the company. UBS Group started coverage on Recro Pharma in a research note on Tuesday. They set an “outperform” rating for the company. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Recro Pharma has a consensus rating of “Buy” and an average target price of $13.75.
In related news, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $9.50, for a total value of $973,180.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the firm’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $9.56, for a total value of $126,086.84. Following the completion of the sale, the insider now directly owns 2,243,064 shares of the company’s stock, valued at approximately $21,443,691.84. The disclosure for this sale can be found here. Insiders sold 860,414 shares of company stock valued at $8,289,916 in the last ninety days. 21.60% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece was posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.thestockobserver.com/2018/02/17/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-recro-pharma-reph-stock-price.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.